Literature DB >> 2004374

Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.

H K Silver1, B L Archibald, J Ragaz, A J Coldman.   

Abstract

Relative operating characteristic (ROC) analysis was used to examine the clinical applicability of 3 breast carcinoma tumor markers, CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen. Each tumor marker was quantitated in single serum samples collected from 100 normal blood donors, 60 patients with nonmalignant diseases, 33 women at high risk for breast carcinoma, 30 patients with malignancies other than breast carcinoma, and 158 breast carcinoma patients including 67 with no evidence of disease following surgery, 46 with a tumor burden less than 5 g, and 45 with a tumor burden greater than 5 g. These were used to construct models for early diagnosis among those at high risk for breast carcinoma, the influence of nonmalignant disease on early diagnosis, discrimination of breast carcinoma from other adenocarcinomas, detection of early recurrence, and assessment of change in tumor burden. For each model ROC data permitted the unbiased selection of the most appropriate critical values based on the interaction of sensitivity and specificity. ROC analysis indicated that in practice the assays were remarkably similar. While CA 15.3 generally performed best, there was significant variation among models. Optimal marker selection can thus depend on specific clinical application. In some cases ROC identified a combination of markers as superior to any single assay, but this was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004374

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Decision Making Using Postoperative CEA and CA 15-3 for Detection of Breast Cancer Recurrence.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

2.  Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.

Authors:  E Vizcarra; A Lluch; R Cibrián; F Jarque; V Alberola; V Belloch; J García-Conde
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  Simple method for comparing reliability of two serum tumour markers in breast carcinoma.

Authors:  D P O'Brien; D B Gough; R Skehill; H Grimes; H F Given
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

4.  Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.

Authors:  Andrea Nicolini; Gianna Tartarelli; Angelo Carpi; Maria Rita Metelli; Paola Ferrari; Loretta Anselmi; Massimo Conte; Piero Berti; Paolo Miccoli
Journal:  BMC Cancer       Date:  2006-11-20       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.